Pharmacogenetics and Pharmacogenomics as Enabling Technologies for Precision Drug Development and Personalized...

Differences among individuals in susceptibility to adverse drug reactions are strongly influenced by genetic variation affecting drug metabolism, transport, immune response, and pharmacodynamics pathways, presenting both challenges and opportunities for drug discovery and development. Genetic and genomic variation can modify pharmacokinetics, pharmacodynamics, immunemediated toxicity, treatment resistance, and biomarker-defined therapeutic benefit, making pharmacogenetics and pharmacogenomics central components of precision medicine. The primary aim of this review is to synthesize how pharmacogenetics and pharmacogenomics function as enabling technologies across the pharmaceutical and clinical domains, with emphasis on biomarker-guided drug development, patient stratification, safety optimization, regulatory translation, precision oncology, sex-related variability, population diversity, artificial intelligence, and multi-omics integration. The review also elucidates the distinction between single-gene pharmacogenetics and genome-wide pharmacogenomics and discusses the practical requirements, procedures, advantages, and challenges associated with implementation. Future progress will depend on harmonized standards, diverse population datasets, preemptive testing linked to electronic health records, explainable artificial intelligence, multi-omics validation, and equitable access to genomic prescribing tools, ensuring that precision therapeutics improve drug safety and efficacy across populations.